Free tool
FAERS Monitor: Trulance
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 208745 or its brand name (Trulance, Plecanatide). Reports on generic versions are filed under their own applications.
Reports
2,075
Serious
758
37% of reports
Hospitalization
297
Death reported
77
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- diarrhoea405
- nausea181
- drug ineffective175
- constipation174
- abdominal distension120
- fatigue119
- abdominal pain113
- abdominal pain upper108
- headache108
- dizziness102
- pain102
- product use in unapproved indication77
- dyspnoea76
- malaise75
- vomiting75
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2016 | 4 |
| 2017 | 150 |
| 2018 | 205 |
| 2019 | 217 |
| 2020 | 262 |
| 2021 | 224 |
| 2022 | 201 |
| 2023 | 199 |
| 2024 | 187 |
| 2025 | 196 |
| 2026 | 230 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,084 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| abdominal distensionSignal | 120 | 11.7 | 9.8 | 1,164 |
| constipationSignal | 174 | 8.1 | 7.0 | 1,085 |
| diarrhoeaSignal | 405 | 6.4 | 5.8 | 1,882 |
| abdominal pain upperSignal | 108 | 5.3 | 4.4 | 378 |
| abdominal painSignal | 113 | 4.9 | 4.1 | 353 |
| product use in unapproved indicationSignal | 77 | 3.1 | 2.5 | 112 |
| nauseaSignal | 181 | 2.3 | 2.0 | 140 |
| dizzinessSignal | 102 | 2.1 | 1.7 | 57 |
| headache | 108 | 1.7 | 1.5 | 35 |
| malaise | 75 | 1.7 | 1.4 | 23 |
| pain | 102 | 1.7 | 1.4 | 28 |
| vomiting | 75 | 1.6 | 1.3 | 17 |
| fatigue | 119 | 1.5 | 1.3 | 24 |
| dyspnoea | 76 | 1.4 | 1.1 | 7 |
| drug ineffective | 175 | 1.3 | 1.2 | 16 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.